TABLE 5.

Risk differences in total mortality between sulonylurea and metformin monotherapy in a VA cohort starting from the date of first prescription (Rx) using a variety of causal effect estimators.

Method and Sample	One Year after Rx	Two Years after Rx	Five Years after Rx
Unadjusted 2004–2009	2.6% (2.3%, 2.8%)	5.3% (4.9%,5.7%)	12.6% (11.9%, 13.2%)
Unadjusted 2010–2014	2.4% (2.0%, 2.7%)	5.1% (4.6%, 5.7%)	12.5% (11.7%, 13.4%)
CBPS 2004–2009	2.3% (2.1%, 2.6%)	5.0% (4.7%, 5.4%)	12.2% (11.6%, 12.7%)
CBPS 2010–2014	1.0% (0.7%, 1.4%)	2.0% (1.5%, 2.5%)	4.1% (3.4%, 4.9%)
Transported 2004–2009	0.8% (0.5%, 1.1%)	1.9% (1.4%, 2.3%)	4.0% (3.4%, 4.6%)
Data-Fusion	0.9% (0.7%, 1.1%)	2.1% (1.7%, 2.4%)	4.2% (3.7%, 4.7%)